Atopic Dermatitis

Patients with atopic dermatitis who are on Janus kinase inhibitors did not show an increased risk for venous thromboembolism, according to a study.

Subcutaneous and sublingual immunotherapy for aeroallergens improved disease severity and quality of life among patients with atopic dermatitis, according to a review published in The Journal of Allergy & Clinical Immunology.

For allergists interested in dermatology-focused findings from the European Academy of Dermatology and Venereology Congress but who could not attend the meeting this year in Milan, Healio presents this list of seven studies that may be relevant to your practice.

The European Medicines Agency has recommended extending the use of Adtralza in the European Union to adolescents with moderate to severe atopic dermatitis, according to a LEO Pharma press release.

Dupilumab significantly improved the signs and symptoms of moderate to severe atopic dermatitis as well as quality of life among patients aged 6 months to younger than 6 years, according to a study published in The Lancet.

MILAN — A basket study of a new topical phosphodiesterase 4 inhibitor demonstrated efficacy superior to that of placebo in mild to moderate plaque psoriasis.

MILAN — Patients with atopic dermatitis of the head and neck who did not have success with topical therapy experienced greater improvement with rocatinlimab treatment.

MILAN — Maintenance dosing of lebrikizumab every 4 weeks showed similar efficacy as dosing every 2 weeks in patients with atopic dermatitis, according to a presentation at the European Academy of Dermatology and Venereology Congress.

MILAN — Adult-onset dermatitis has distinct TH1 activation compared with adults who have childhood-onset atopic dermatitis, showing two separate endotypes defined by age of onset.

Although treatment was well tolerated, astegolimab did not effectively improve primary or secondary outcome measurements in atopic dermatitis, according to a study published in The Journal of Allergy and Clinical Immunology.